Rheumatoid arthritis - adalimumab, etanercept and infliximab: appeal panel's decision
The Appeal Panel met on 29 September 2008 to consider the appeals lodged against the Final Appraisal Determination (FAD) for this appraisal.
The appeal was upheld under grounds 1 and 2 and the appeal panel has recommended that the appraisal of the sequential use of the three drugs after failure of the first TNF inhibitor should be restarted as a new appraisal. We have written to the Department of Health to ask whether they want us to do this and we will update this page of the web site when we have their response. As a consequence of the appeal panel's decision, this appraisal is now ended.
This page was last updated: 30 March 2010